Evidence map›Paper›PMID 23505554›Full record

ArticlePloS one2013

Somatic mutations, allele loss, and DNA methylation of the Cub and Sushi Multiple Domains 1 (CSMD1) gene reveals association with early age of diagnosis in colorectal cancer patients.

Austin Y Shull, Megan L Clendenning, Sampa Ghoshal-Gupta, Christopher L Farrell, Hima V Vangapandu, Larry Dudas, Brent J Wilkerson, Phillip J Buckhaults

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 35 citations in OpenAlex.

  1. Potential Association of theInternational journal of molecular sciences · 2025
    Article
  2. Article
  3. Review
  4. Article
  5. Cancers · 2022
    Article
  6. Article
  7. Article
  8. Article
  9. The Journal of biological chemistry · 2020
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Exome Sequencing Reveals AMER1 as a Frequently Mutated Gene in Colorectal Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Austin Y ShullGeorgia Health Sciences University Cancer Center, Georgia Health Sciences University, Augusta, Georgia, United States of America.
Megan L Clendenning
Sampa Ghoshal-Gupta
Christopher L Farrell
Hima V Vangapandu
Larry Dudas
Brent J Wilkerson
Phillip J Buckhaults
Augusta University Health · USNortheast Georgia Medical Center · USPresbyterian College · USThe University of Texas MD Anderson Cancer Center · USUniversity of California Davis Medical Center · US

Funding

A Genetic Model for Early-Onset Breast and Colon Cancer in African AmericansU01CA158428 · NCI · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI BUCKHAULTS, PHILLIP JOE, BUNZ, FRED · 2012 to 2016
$1.5M
Molecular Predictors of Colorectal Cancer RecurrenceR21CA127683 · NCI · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI BUCKHAULTS, PHILLIP JOE · 2009 to 2010
$353k
NCI NIH HHS 7R21CA127683NCI NIH HHS R21 CA127683NCI NIH HHS U01 CA158428
6 · The paper itself

Abstract

backgroundThe Cub and Sushi Multiple Domains 1 (CSMD1) gene, located on the short arm of chromosome 8, codes for a type I transmembrane protein whose function is currently unknown. CSMD1 expression is frequently lost in many epithelial cancers. Our goal was to characterize the relationships between CSMD1 somatic mutations, allele imbalance, DNA methylation, and the clinical characteristics in colorectal cancer patients.

methodsWe sequenced the CSMD1 coding regions in 54 colorectal tumors using the 454FLX pyrosequencing platform to interrogate 72 amplicons covering the entire coding sequence. We used heterozygous SNP allele ratios at multiple CSMD1 loci to determine allelic balance and infer loss of heterozygosity. Finally, we performed methylation-specific PCR on 76 colorectal tumors to determine DNA methylation status for CSMD1 and known methylation targets ALX4, RUNX3, NEUROG1, and CDKN2A.

resultsUsing 454FLX sequencing and confirming with Sanger sequencing, 16 CSMD1 somatic mutations were identified in 6 of the 54 colorectal tumors (11%). The nonsynonymous to synonymous mutation ratio of the 16 somatic mutations was 15:1, a ratio significantly higher than the expected 2:1 ratio (p = 0.014). This ratio indicates a presence of positive selection for mutations in the CSMD1 protein sequence. CSMD1 allelic imbalance was present in 19 of 37 informative cases (56%). Patients with allelic imbalance and CSMD1 mutations were significantly younger (average age, 41 years) than those without somatic mutations (average age, 68 years). The majority of tumors were methylated at one or more CpG loci within the CSMD1 coding sequence, and CSMD1 methylation significantly correlated with two known methylation targets ALX4 and RUNX3. C:G>T:A substitutions were significantly overrepresented (47%), suggesting extensive cytosine methylation predisposing to somatic mutations.

conclusionsDeep amplicon sequencing and methylation-specific PCR reveal that CSMD1 alterations can correlate with earlier clinical presentation in colorectal tumors, thus further implicating CSMD1 as a tumor suppressor gene.

Indexed as

DNA MethylationLoss of HeterozygosityMutationAdultAgedAged, 80 and overAge FactorsAllelesAllelic ImbalanceCell Line, TumorColorectal NeoplasmsFemaleHumansMaleMembrane ProteinsMicrosatellite InstabilityCSMD1 protein, humanMembrane ProteinsTumor Suppressor Proteins

Identifiers

PMID23505554
PMCPMC3591376
OpenAlexW2057845241

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.